GSK's candidate Mycobacterium tuberculosis vaccine 692342

BIOLOGICAL3 trials

Sponsors

GlaxoSmithKline

Conditions

TuberculosisTuberculosis (TB)

Phase 1

Safety and Immunogenicity of a Candidate Tuberculosis (TB) Vaccine Given to PPD-Negative Adults

CompletedNCT00730795

GlaxoSmithKlineTuberculosis (TB)

Start: 2004-01-31Updated: 2008-08-08

Phase 2

Safety and Immunogenicity of 2 Formulations of Tuberculosis Vaccine GSK692342 Given at 0,1 Months to Healthy Adults

CompletedNCT00397943

GlaxoSmithKlineTuberculosis

Start: 2006-11-15End: 2009-12-01Updated: 2019-06-19

Safety and Immunogenicity of a Candidate Tuberculosis (TB) Vaccine in HIV-positive Adults.

CompletedNCT00707967

GlaxoSmithKlineTuberculosis

Start: 2008-06-30End: 2009-05-27Updated: 2018-08-24

Related Papers

Whole blood can be used as an alternative to isolated peripheral blood mononuclear cells to measure in vitro specific T-cell responses in human samples

Journal of Immunological Methods2021-01-237 citations

Safety and immunogenicity of the M72/AS01 candidate tuberculosis vaccine in HIV-infected adults on combination antiretroviral therapy: a phase I/II, randomized trial.

2014-07-0143 citations

Responses to A(H1N1)pdm09 Influenza Vaccines in Participants Previously Vaccinated With Seasonal Influenza Vaccine: A Randomized, Observer-Blind, Controlled Study

The Journal of Infectious Diseases2014-05-2621 citations

The candidate tuberculosis vaccine Mtb72F/AS02A: Tolerability and immunogenicity in humans.

2009-07-2774 citations